✦ LIBER ✦

Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

✍ Scribed by Gaballa, Mahmoud R.; Besa, Emmanuel C.

Book ID: 121759755
Publisher: Springer
Year: 2014
Tongue: English
Weight: 631 KB
Volume: 93
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-014-2022-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lenalidomide in the Myelodysplastic Synd

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

✍ List, Alan; Dewald, Gordon; Bennett, John; Giagounidis, Aristotle; Raza, Azra; F 📂 Article 📅 2006 🏛 Massachusetts Medical Society 🌐 English ⚖ 203 KB

Lenalidomide active in myelodysplastic s

Lenalidomide active in myelodysplastic syndrome without 5q deletion

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Lenalidomide on alternative days is effe

Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion

✍ Marzia Defina; Michela Rondoni; Alessandro Gozzetti; Lara Aprile; Ida Chitarrell 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

A critical review of the molecular patho

A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q − myelodysplastic syndromes

✍ Voutsadakis, Ioannis A.; Cairoli, Anne 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 494 KB

Lenalidomide for del(5q) and Non-del(5q)

Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

✍ Aristoteles A.N. Giagounidis 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 874 KB

Treatment of myelodysplastic syndromes w

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

✍ C. Kelaidi; S. Park; S. Brechignac; L. Mannone; N. Vey; H. Dombret; L. Aljassem; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 98 KB